


2.4.6-Trinitrophenol (2,4,6-トリニトロフェノール)

Experimental Data without Metabolic Activation

(C9605-1/2)

| | |
|-------------------------------|---|
| Chemical Name | ; 2,4,6-Trinitrophenol |
| Synonym | ; Picric acid Phenol, 2,4,6-trinitro- ピクリン酸 |
| Molecular Weight | ; 229.11 |
| Melting Point | ; 122.5°C [CHCD] |
| Boiling Point | ; — |
| Flashing Point | ; — |
| Molecular Formula | ; C ₆ H ₃ N ₃ O ₇ |
| Chemical Structure |  |
| CAS No. | ; 88-89-1 |
| MITI No. | ; (3)-823 |
| ML No. | ; — |
| Specified Chemical Substances | ; — |
| Source of Substance | ; Wako Jyunyaku Kogyo Co., Ltd. |
| Lot No. | ; PTQ3878 |
| Purity | ; 99.5% |
| Vehicle | ; DMSO |

| Substance | Time (h) | Concen- tration (mg/ml) | No. of Metaphase | Polyploid | | Cell with Structural Chromosome Aberration (%) | | | | | | | | |
|---------------------------|----------|-------------------------------|------------------------------|-----------|----------------|--|------|------|-----------|------------|--------|-------|----------------|---|
| | | | | (%) | Judge- ment | Gap | ctb | cte | Chromatid | Chromosome | Others | Total | Judge- ment | |
| DMSO | 24 | 1.0% | 200 | 1 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| | 48 | 1.0% | 200 | 0.5 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Test Chemical | 24 | 0.0078 | 200 | 0 | — | 0 | 0.5 | 1 | 0 | 0 | 0 | 1.5 | 1.5 | — |
| | | 0.031 | 200 | 1.5 | — | 0 | 1.5 | 1 | 0 | 0 | 0 | 1.5 | 1.5 | — |
| | | 0.13 | 200 | 0.5 | — | 1.5 | 5.5 | 2 | 0 | 0 | 0 | 7.5 | 9 | ± |
| | | 0.5 | 200 | 0.5 | — | 1.5 | 18 | 6 | 0 | 0 | 0 | 22 | 23.5 | + |
| | | 2.0 | No obserbation for metaphase | | | | | | | | | | | |
| | 48 | 0.13 | 200 | 0.5 | — | 0.5 | 2.5 | 1.5 | 0 | 0 | 0 | 3.5 | 4 | — |
| | | 0.25 | 200 | 1.5 | — | 2 | 17 | 4 | 0 | 0 | 0 | 19.5 | 21 | + |
| | | 0.5 | 200 | 0.5 | — | 3 | 48 | 25 | 0 | 0 | 0 | 61.5 | 62 | + |
| | | 1.0 | 121 | 0 | — | 7.4 | 71.9 | 27.3 | 0 | 0 | 0 | 75.2 | 77.7 | + |
| | | 2.0 | No obserbation for metaphase | | | | | | | | | | | |
| Positive Control [MMC] | 24 | 0.00004 | 200 | 1 | — | 0.5 | 11.5 | 11.5 | 0 | 0 | 0 | 21 | 21.5 | + |
| | 48 | 0.00004 | 200 | 2 | — | 0.5 | 14.5 | 27 | 0.5 | 0 | 0 | 35.5 | 35.5 | + |

Judgement for
Chromosomal Aberration in CHL ; Positive

IARC Evaluation ; not yet cited

Experimental Data with Metabolic Activation

| Substance | Treatment | | | No. of Metaphase | Polyploid | | Cell with Structural Chromosome Aberration (%) | | | | | | | | | | |
|--------------------------|-----------|-------------------------------|-----|------------------|-----------|----------------|--|------|-----------|-----|------------|----|--------|-------|---|----------------|--|
| | S9 mix | Concen-t ration (mg/ml) | | | (%) | Judge- ment | Gap | | Chromatid | | Chromosome | | Others | Total | | Judge- ment | |
| | | | | | | | g | ctb | cte | csb | cse | -g | | +g | | | |
| DMSO | — | 1.0% | 200 | 1 | — | 0 | 0.5 | 0.5 | 0 | 0 | 0 | 0 | 1 | 1 | — | | |
| | + | 1.0% | 200 | 1 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | | |
| Test Chemical | — | 0.5 | 200 | 2 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | | |
| | | 1.0 | 200 | 3 | — | 0 | 2.5 | 0 | 0 | 0 | 0 | 0 | 2.5 | 2.5 | — | | |
| | | 1.5 | 200 | 1.5 | — | 0 | 2.5 | 1 | 0 | 0 | 0 | 0 | 3.5 | 3.5 | — | | |
| | | 2.0 | 200 | 1.5 | — | 0.5 | 2.5 | 1.5 | 0 | 0 | 0 | 0 | 3.5 | 4 | — | | |
| | | 2.5 | 200 | 0 | — | 2.5 | 7.5 | 4.5 | 0 | 0 | 0 | 0 | 10.5 | 12.5 | + | | |
| | + | 0.5 | 200 | 2 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | | |
| | | 1.0 | 200 | 1 | — | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0.5 | 0.5 | — | | |
| | | 1.5 | 200 | 3.5 | — | 0 | 0.5 | 0.5 | 0 | 0 | 0 | 0 | 1 | 1 | — | | |
| | | 2.0 | 200 | 1 | — | 0.5 | 0.5 | 3 | 0 | 0 | 0 | 0 | 3.5 | 4 | — | | |
| | | 2.5 | 200 | 2.5 | — | 0 | 8 | 9.5 | 0 | 0 | 0 | 0 | 13 | 13 | + | | |
| Positive Control [B[a]P] | — | 0.01 | 200 | 1.5 | — | 0 | 0.5 | 0.5 | 0 | 0 | 0 | 0 | 1 | 1 | — | | |
| | + | 0.01 | 200 | 0.5 | — | 0 | 18 | 40.5 | 0 | 0 | 0 | 45 | 45 | 45 | + | | |

※ Test conditions: Treatment time ; 6h, Recovery time ; 18h

※ There was no observation for metaphase with treatment of -S9 and +S9 at 3.0mg/ml.